Executive Briefing - Financial innovation
This article was originally published in Scrip
Executive Summary
How will the biopharmaceutical industry get through the capital crisis? In the face of unprecedented industry challenges, companies are stripping their businesses down to the essentials, showing increased flexibility and novelty in dealmaking, and concentrating on the medium term. Emma Palmer Foster weighs up the innovative survival strategies available to them